Cone Beam CT Scanning in Lung and Bladder Cancer.

Sponsor
AHS Cancer Control Alberta (Other)
Overall Status
Completed
CT.gov ID
NCT00469066
Collaborator
Cross Cancer Institute (Other)
22
1
35
0.6

Study Details

Study Description

Brief Summary

To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    22 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging
    Study Start Date :
    May 1, 2007
    Actual Primary Completion Date :
    Aug 1, 2009
    Actual Study Completion Date :
    Apr 1, 2010

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Patient has biopsy proven limited stage SCLC

      • receiving radical concurrent chemoradiotherapy

      • no prior chest RT

      • no prior surgical resection of lung tumor

      • no prior chemotherapy

      • patients' lung tumors should be centrally-located to minimize the effect of respiratory motion

      • patient has biopsy proven TCC bladder

      • receiving radical concurrent chemoradiotherapy or RT alone

      • no prior chemotherapy

      • patient signs study-specific consent form

      Exclusion Criteria:
      • mixed small cell and non small cell histology

      • patient not being treated with concurrent chemoradiotherapy

      • chemoradiotherapy given sequentially

      • previous chest RT

      • previous chemotherapy

      • prior surgical resection of lung mass

      • patient ineligible for pelvic RT

      • patient does not sign study consent

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Cross Cancer Institute Edmonton Alberta Canada

      Sponsors and Collaborators

      • AHS Cancer Control Alberta
      • Cross Cancer Institute

      Investigators

      • Principal Investigator: Don Yee, MD, AHS Cancer Control Alberta

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      AHS Cancer Control Alberta
      ClinicalTrials.gov Identifier:
      NCT00469066
      Other Study ID Numbers:
      • LU-11-0073
      First Posted:
      May 4, 2007
      Last Update Posted:
      Feb 24, 2016
      Last Verified:
      Dec 1, 2011

      Study Results

      No Results Posted as of Feb 24, 2016